Interview opportunity: JDRF celebrates the announcement of Dexcom G6 CGM System's Availability in Canada
JDRF shares the excitement of the type 1 diabetes community around today’s arrival of the Dexcom G6,” said Dave Prowten, President an...Read More
JDRF advocates for all Canadians living with type 1 diabetes to be eligible for the Disability Tax Credit
JDRF believes that every Canadian with type 1 diabetes should qualify for the Disability Tax Credit.
The JDRF Revolution Ride challenges Canadians to go further and raise funds to defeat type 1 diabetes.
Eli Lilly Canada Inc. (Lilly Canada) and JDRF Canada have awarded two promising researchers each with a post-doctoral fellowship grant to pursue studies in type 1 diabetes.
JDRF has awarded Dr. James Johnson and his team from the University of British Columbia (UBC) a grant of US$150,000 for a one-year study on whether insulin levels produced by transplanted pancreatic beta cells can be controlled and stabilized.
JDRF and Lilly Canada fund UHN research on new stem cell therapies aimed at eliminating the need for insulin injections.
Marley Greenberg from Thornhill, Ontario, will serve as the Canadian delegate at JDRF’s (Juvenile Diabetes Research Foundation) 2017 Children’s Congress, taking place from July 24 to 26 in Washington, D.C.
In June, over 40,000 Canadians across the country will rally together at the 2017 JDRF TELUS Walk to Cure Diabetes, to raise awareness and funds and help change the face of type 1 diabetes (T1D) forever.
JDRF and Lilly Canada requesting applications from postdoctoral fellows engaged in clinical type 1 diabetes research
JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce that Eli Lilly Canada Inc. (Lilly Canada) has provided $120,000 in support of two CCTN postdoctoral fellows for one year in the sum of $60,000 each.
Canadian business executive, Tom Gaglardi, President of Northland Properties Corporation and owner of the Dallas Stars, presented a generous $3M gift to JDRF Canada to support type 1 diabetes research in the areas of encapsulation, and beta cell replacement and regeneration.
Building a strong partnership to accelerate type 1 diabetes clinical trials research